Loading...
XLON
FAB
Market cap9mUSD
Jul 11, Last price  
6.30GBP
1D
-0.79%
1Q
-3.82%
IPO
-95.91%
Name

Fusion Antibodies PLC

Chart & Performance

D1W1MN
P/E
—
P/S
630.31
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.25%
Rev. gr., 5y
-12.24%
Revenues
1m
-60.84%
404,997723,046909,2941,481,2651,913,9562,690,7442,181,8383,895,0004,165,0004,799,0002,901,0001,136,000
Net income
-2m
L-14.25%
-468,737-113,538-85,1121,154,092119,954-699,941-1,264,382-697,000-2,899,000-1,200,000-2,596,000-2,226,000
CFO
-2m
L+0.80%
00-182,050346,570-37,37477,192-1,098,350-166,000-1,151,000-333,000-1,755,000-1,769,000
Earnings
Sep 03, 2025

Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
URL
https://fusionantibodies.com/
IPO date
Dec 18, 2017
Employees
55
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
1,136
-60.84%
2,901
-39.55%
Cost of revenue
3,428
5,734
Unusual Expense (Income)
NOPBT
(2,292)
(2,833)
NOPBT Margin
Operating Taxes
(63)
(263)
Tax Rate
NOPAT
(2,229)
(2,570)
Net income
(2,226)
-14.25%
(2,596)
116.33%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,808
BB yield
-134.78%
Debt
Debt current
20
35
Long-term debt
66
80
Deferred revenue
Other long-term liabilities
20
20
Net debt
(1,113)
(80)
Cash flow
Cash from operating activities
(1,769)
(1,755)
CAPEX
(2)
(114)
Cash from investing activities
1,000
(114)
Cash from financing activities
2,770
7
FCF
(1,313)
(1,590)
Balance
Cash
1,199
195
Long term investments
Excess cash
1,142
50
Stockholders' equity
(5,950)
(6,524)
Invested Capital
7,806
7,606
ROIC
ROCE
EV
Common stock shares outstanding
55,556
26,015
Price
0.04
-90.26%
0.39
-35.83%
Market cap
2,083
-79.20%
10,016
-35.66%
EV
970
9,936
EBITDA
(2,072)
(2,461)
EV/EBITDA
Interest
5
4
Interest/NOPBT